Trace Biosciences
-
FDA Clears First Nerve-Specific Fluorescent Agent for Human Trials
Trace Biosciences, Inc., a clinical-stage biotechnology company focused on nerve-targeted imaging, announced that the U.S. Food and Drug Administration has approved its Investigational New Drug (IND) application for LGW16-03, the company’s first nerve-specific fluorescent imaging agent. This clearance allows Trace to begin first-in-human studies to assess the safety and performance of LGW16-03 during surgery. Helping…